Conditions: Healthy Volunteers
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 35
Healthy volunteers: yes

Brief summary:
The study will evaluate the effect of different particle size of LY2140023. The study involves 4 single doses of 80 milligrams (mg) LY2140023 taken as 1 tablet by mouth with a washout period of at least 3 days between doses. This study will last approximately 60 days not including screening. Screening is required within 30 days prior to study entry.

Detailed description:

Arms:
arm 1: LY2140023: 80 mg, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period. arm 2: LY2140023: 80 mg, low particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period. arm 3: LY2140023: 80 mg, medium particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period. arm 4: LY2140023: 80 mg, high particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.

Interventions: intervention 1: LY2140023 Reference form intervention 2: LY2140023 Test-Low intervention 3: LY2140023 Test-Medium intervention 4: LY2140023 Test-High
Intervention descriptions: intervention 1: 80-mg tablet administered orally intervention 2: 80-mg tablet administered orally intervention 3: 80-mg tablet administered orally intervention 4: 80-mg tablet administered orally

Protocol document: